Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.

Cancer genetics - 1 Aug 2020

Sutcliffe Erin G, Stettner Amy R, Miller Stacey A, Solomon Sheila R, Marshall Megan L, Roberts Maegan E, Susswein Lisa R, Arvai Kevin J, Klein Rachel T, Murphy Patricia D, Hruska Kathleen S

Abstract excerpt

PURPOSE: Although CHEK2 is a well-established cancer gene, questions remain including whether risks vary substantially between different variants and whether biallelic carriers have higher risks than heterozygotes. We report on a cohort of individuals with CHEK2 pathogenic and likely pathogenic variants (collectively, PV) in order to better characterize this gene. METHODS: We retrospectively queried samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Genetic Testing

Share to Heterozygote

Share to Neoplasms

Share to Prevalence

Share to United States

Source

Identifiers

PMID: 32805687
DOI: 10.1016/j.cancergen.2020.07.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.PMID 32805687Read ↗

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.Semantic proximity Read ↗

Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.Semantic proximity Read ↗

The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.Semantic proximity Read ↗

Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.Semantic proximity Read ↗

Genomic ascertainment of<i>CHEK2</i>-related cancer predispositionSemantic proximity Read ↗

High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.Semantic proximity Read ↗

Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.Semantic proximity Read ↗

Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes.Semantic proximity Read ↗

CHEK2 Germline Variants and Their Clinical Implications: Experience from a Turkish Hereditary Cancer Cohort.Semantic proximity Read ↗

Genomic Ascertainment of CHEK2-Related Cancer Predisposition.Semantic proximity Read ↗

Germline variant profiling of CHEK2 sequencing variants in breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.